In a nutshell This study evaluated the role of 18F-fluciclovine-PET-CT versus conventional imaging (bone scan and either CT or MRI) alone for salvage radiotherapy (RT) after prostate surgery for the treatment of patients with localized prostate cancer (PCa). The data showed that including 18F-fluciclovine-PET-CT into the decision-making process for RT...
Read More
In a nutshell This study analyzed the effectiveness and safety of new hormonal therapies (nHTs) in patients with non-metastatic castration-resistant prostate cancer (CRPC). The authors concluded that nHT improved the outcomes of these patients. Some background CRPC is an aggressive type of prostate cancer that is resistant to androgen...
Read More
In a nutshell This article looked at the impact of nerve-sparing (NS) surgery on positive surgical margin (PSM) location and the recurrence of tumors in patients following radical prostatectomy (RP; prostate removal surgery). The authors found that having NS surgery on both sides of the prostate increased the risk of PSM and was associated with a higher...
Read More
In a nutshell This study investigated the association between the lowest PSA value after radical prostatectomy (RP; surgery to remove the prostate) and the occurrence of biochemical recurrence (BCR) in patients with localized prostate cancer (PCa). The study found that a higher PSA value after RP and a shorter time to reach this...
Read More
In a nutshell The study aimed to understand the long-term outcomes of focal laser therapy (FLT) in patients with prostate cancer. The study showed that this treatment has long-term survival without recurrence in certain patients. Some background Surgical removal of the prostate gland is often recommended as a treatment for...
Read More
In a nutshell This study investigated the outcomes and effectiveness of administering additional (adjuvant) androgen deprivation therapy (A-ADT) for long-term after radiotherapy (RT) in high-risk or very high-risk locally advanced prostate cancer (LAPC). The study found that the addition of A-ADT longer than 1 year after RT showed good treatment outcomes...
Read More
In a nutshell This study investigated the effectiveness of phosphodiesterase-5 (PDE5) inhibitor tadalafil (Cialis) for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) after low-dose-rate (LDR) brachytherapy (BT) in patients with localized prostate cancer. The data showed that tadalafil improved the LUTS and ED outcomes...
Read More
In a nutshell This study analyzed the urinary, sexual, and tumor control outcomes of robotic-assisted laparoscopic radical prostatectomy (RARP) over time in patients with localized prostate cancer. The study found that analyzing these three outcomes is beneficial for these patients. Some background Localized prostate cancer (PCa) is a form of...
Read More
In a nutshell This trial is looking to examine the use of a new treatment software (UroNAV Ablation) system in treating confined prostate cancer with cryoablation. The main outcomes to be measured will be device/treatment-related complications and tumor control. This trial is being carried out in New York, US. The details Localized...
Read More
In a nutshell This study investigated the effectiveness and functional outcomes of using the Retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) as a salvage treatment for patients with localized prostate cancer (PCa). The study found that the sRS-RARP approach was associated with good urinary and oncological outcomes in these...
Read More
In a nutshell This study evaluated the long-term outcomes of patients who underwent whole-gland high-intensity focused ultrasound (HIFU) for non-metastatic prostate cancer. The data showed that HIFU has favorable outcomes in low- and intermediate-risk groups of patients. Some background HIFU is a treatment option for prostate...
Read More
In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...
Read More
